(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis. - 2Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- 3Israel launches new wave of attacks against Hezbollah in Beirut
- 4Gym tied to outbreak of obscure disease that spreads through mist
- 5Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- Parents who delay baby's first vaccines also likely to skip measles shots
- German finance minister seeks better market access in China talks
- The Best 10 Innovation Developments of the Year
- 8 key takeaways from Savannah Guthrie's 'Today' interview on the disappearance of her mother
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Novartis eyes more bolt-on acquisitions, CEO says
- Five EU states press for windfall taxes on fossil energy sector
- The most effective method to Offset Album Rates with Liquidity Needs
